Long-Term Effectiveness and Drug Survival of Apremilast in Treating Psoriasis: A Real-World Experience.

Distel, Julian; Cazzaniga, Simone; Seyed Jafari, S. Morteza; Emelianov, Vladimir; Schlapbach, Christoph; Yawalkar, Nikhil; Heidemeyer, Kristine (2022). Long-Term Effectiveness and Drug Survival of Apremilast in Treating Psoriasis: A Real-World Experience. Dermatology, 238(2), pp. 267-275. Karger 10.1159/000515763

Full text not available from this repository. (Request a copy)

BACKGROUND

Apremilast is an oral phosphodiesterase 4 (PDE4) inhibitor used for the treatment of moderate to severe psoriasis. Long-term data on the effectiveness and drug survival of patients treated with apremilast are limited.

OBJECTIVE

The aim of this study was to analyze the characteristics, effectiveness, and drug survival of patients treated with apremilast in a real-world setting.

METHODS

We conducted a retrospective cohort study of patients with psoriasis who received at least 1 dose of apremilast between 2015 and 2018. We documented sex; age; type, duration, and severity (using Psoriasis Area Severity Index [PASI] and Dermatology Life Quality Index [DLQI]) of psoriasis; comorbidities; previous treatment modalities; adverse events; and reasons for therapy discontinuation. For drug survival, estimates and efficacy analysis with Kaplan-Meier statistics were used.

RESULTS

The drug survival rate of the 93 reviewed patients was 69.5% at 6 months, 34.7% at 12 months, and 25.8% at 24 months after initiating therapy. The median survival duration was 8.0 months. Therapy was discontinued in 66.6 and 27.8% due to loss of efficacy and adverse events, respectively. At 24 months, 35.9% had achieved PASI75 response and 23.7% had achieved PASI90 response. Most observed adverse events were gastrointestinal issues, weight loss, and headache.

CONCLUSIONS

Apremilast is an effective and well-tolerated therapy for patients with moderate to severe psoriasis, especially for patients with difficult-to-treat locations and/or contraindications to other biologics. Furthermore, apremilast was used for patients with a history of nonresponse to biologics and was favored for patients with relatively low PASI (<10) and a high DLQI.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology

UniBE Contributor:

Cazzaniga, Simone; Jafari, Morteza; Emelianov, Vladimir; Schlapbach, Christoph; Yawalkar, Nikhil and Heidemeyer, Kristine

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1018-8665

Publisher:

Karger

Language:

English

Submitter:

Andrea Studer-Gauch

Date Deposited:

04 Jan 2022 15:30

Last Modified:

12 Mar 2022 00:12

Publisher DOI:

10.1159/000515763

PubMed ID:

34091455

Uncontrolled Keywords:

Apremilast Drug survival Psoriasis Real world

URI:

https://boris.unibe.ch/id/eprint/162121

Actions (login required)

Edit item Edit item
Provide Feedback